About
Neurological & psychiatric diseases
Areas of Focus
Categories
Small Molecule PharmaceuticalVirginia, DC, DE & Maryland
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
2
As Collaborator
2
Total Enrollment
254
By Phase
PHASE2: 3PHASE2/PHASE3: 1
By Status
RECRUITING: 2WITHDRAWN: 1COMPLETED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06919926Collaborator
Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults
PHASE2Recruiting
60 participants
Started: Apr 17, 2025 · Completed: May 31, 2028
NCT05986721Lead Sponsor
Clinical Trial of AGB101 for Mild Cognitive Impairment
PHASE2Withdrawn
Started: Dec 3, 2024 · Completed: Dec 31, 2028
NCT05824728Collaborator
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
PHASE2Recruiting
30 participants
Started: Sep 28, 2023 · Completed: Sep 30, 2026
NCT03486938Lead Sponsor
Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease
PHASE2/PHASE3Completed
164 participants
Started: Dec 13, 2018 · Completed: Nov 2, 2022
Locations (1)
Headquarters
Baltimore, MD, United States
Map
Loading map...